Latest Insider Transactions at Dyne Therapeutics, Inc. (DYN)
This section provides a real-time view of insider transactions for Dyne Therapeutics, Inc. (DYN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Dyne Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Dyne Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 04
2024
|
Jonathan Mc Neill Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,009
+1.36%
|
$0
$0.73 P/Share
|
|
Jan 04
2024
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
42,453
-21.31%
|
$764,154
$18.13 P/Share
|
|
Jan 04
2024
|
Oxana Beskrovnaya Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,674
+10.22%
|
$22,674
$1.03 P/Share
|
|
Jan 03
2024
|
Joshua T Brumm CEO & President |
SELL
Open market or private sale
|
Direct |
51,183
-2.76%
|
$972,477
$19.29 P/Share
|
|
Jan 03
2024
|
Joshua T Brumm CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
51,183
+7.45%
|
$51,183
$1.03 P/Share
|
|
Jan 03
2024
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
13,000
-9.47%
|
$234,000
$18.81 P/Share
|
|
Jan 03
2024
|
Richard William Scalzo SVP, Head of Finance & Admin. |
BUY
Exercise of conversion of derivative security
|
Direct |
13,000
+8.65%
|
$13,000
$1.03 P/Share
|
|
Jan 03
2024
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
17,991
-5.73%
|
$323,838
$18.69 P/Share
|
|
Jan 03
2024
|
Jonathan Mc Neill Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,991
+10.02%
|
$0
$0.73 P/Share
|
|
Jan 03
2024
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
45,326
-7.26%
|
$861,194
$19.3 P/Share
|
|
Jan 03
2024
|
Oxana Beskrovnaya Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
45,326
+16.96%
|
$45,326
$1.03 P/Share
|
|
Jan 02
2024
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
11,900
-7.65%
|
$154,700
$13.1 P/Share
|
|
Dec 14
2023
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
2,376
-1.88%
|
$28,512
$12.02 P/Share
|
|
Dec 12
2023
|
Wildon Farwell Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
978
-0.58%
|
$9,780
$10.55 P/Share
|
|
Dec 11
2023
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,245
-0.79%
|
$12,450
$10.72 P/Share
|
|
Dec 11
2023
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
1,380
-1.08%
|
$13,800
$10.72 P/Share
|
|
Dec 11
2023
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,467
-0.82%
|
$14,670
$10.72 P/Share
|
|
Dec 11
2023
|
Joshua T Brumm CEO & President |
SELL
Open market or private sale
|
Direct |
7,585
-1.28%
|
$75,850
$10.72 P/Share
|
|
Dec 11
2023
|
Wildon Farwell Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,688
-0.98%
|
$16,880
$10.72 P/Share
|
|
Dec 11
2023
|
Susanna Gatti High Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,616
-0.85%
|
$16,160
$10.72 P/Share
|
|
Dec 06
2023
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
1,872
-1.44%
|
$22,464
$12.01 P/Share
|
|
Dec 04
2023
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
681
-0.52%
|
$8,172
$12.01 P/Share
|
|
Nov 15
2023
|
Jonathan Mc Neill Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
96,158
+38.02%
|
-
|
|
Nov 15
2023
|
Richard William Scalzo SVP, Head of Finance & Admin. |
BUY
Grant, award, or other acquisition
|
Direct |
89,742
+40.74%
|
-
|
|
Nov 15
2023
|
Wildon Farwell Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
82,512
+32.45%
|
-
|
|
Nov 15
2023
|
Susanna Gatti High Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
94,893
+33.37%
|
-
|
|
Nov 15
2023
|
Joshua T Brumm CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
358,877
+37.72%
|
-
|
|
Nov 15
2023
|
Oxana Beskrovnaya Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
93,718
+34.48%
|
-
|
|
Nov 02
2023
|
Susanna Gatti High Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
9,939
-9.51%
|
$69,573
$7.4 P/Share
|
|
Sep 18
2023
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
1,290
-3.07%
|
$11,610
$9.41 P/Share
|
|
Sep 18
2023
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,436
-1.67%
|
$12,924
$9.41 P/Share
|
|
Sep 18
2023
|
Joshua T Brumm CEO & President |
SELL
Open market or private sale
|
Direct |
12,032
-4.9%
|
$108,288
$9.41 P/Share
|
|
Sep 18
2023
|
Susanna Gatti High Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,672
-2.49%
|
$24,048
$9.41 P/Share
|
|
Sep 18
2023
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,261
-2.04%
|
$11,349
$9.41 P/Share
|
|
Sep 12
2023
|
Wildon Farwell Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,707
-1.88%
|
$17,070
$10.41 P/Share
|
|
Sep 12
2023
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,484
-1.7%
|
$14,840
$10.41 P/Share
|
|
Sep 12
2023
|
Joshua T Brumm CEO & President |
SELL
Open market or private sale
|
Direct |
7,672
-3.03%
|
$76,720
$10.41 P/Share
|
|
Sep 12
2023
|
Susanna Gatti High Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,635
-1.5%
|
$16,350
$10.41 P/Share
|
|
Sep 12
2023
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,266
-2.01%
|
$12,660
$10.41 P/Share
|
|
Sep 12
2023
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
1,397
-3.21%
|
$13,970
$10.41 P/Share
|
|
Jun 15
2023
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
10,000
-18.7%
|
$120,000
$12.03 P/Share
|
|
Jun 13
2023
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
41,390
-22.66%
|
$496,680
$12.66 P/Share
|
|
Jun 13
2023
|
Richard William Scalzo SVP, Head of Finance & Admin. |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+29.97%
|
$40,000
$1.03 P/Share
|
|
Jun 13
2023
|
Wildon Farwell Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,698
-1.83%
|
$20,376
$12.43 P/Share
|
|
Jun 13
2023
|
Susanna Gatti High Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,625
-1.47%
|
$19,500
$12.43 P/Share
|
|
Jun 13
2023
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,259
-1.96%
|
$15,108
$12.43 P/Share
|
|
Jun 13
2023
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,475
-1.66%
|
$17,700
$12.43 P/Share
|
|
Jun 12
2023
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,000
-1.53%
|
$13,000
$13.0 P/Share
|
|
Jun 12
2023
|
Joshua T Brumm CEO & President |
SELL
Open market or private sale
|
Direct |
187,748
-42.56%
|
$2,252,976
$12.61 P/Share
|
|
Jun 12
2023
|
Joshua T Brumm CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
171,360
+27.98%
|
$171,360
$1.03 P/Share
|